Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01280929|
Recruitment Status : Completed
First Posted : January 21, 2011
Last Update Posted : October 8, 2015
|Condition or disease||Intervention/treatment||Phase|
|High Risk Proliferative Diabetic Retinopathy||Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of ranibizumab||Phase 2|
Panretinal photocoagulation can cause regression of retinal neovascularization and reduce the risk of severe vision loss in people with proliferative diabetic retinopathy. However, this destructive treatment may be associated with side effects (such as: pain, transient blurring, loss of peripheral and/or night vision, increased risk of macular edema and central vision loss) and it is not always efficient in the regression of the neovascularization.
Vascular endothelial growth factor (VEGF) has been shown to play a role in retinal neovascularization and retinal vascular leakage related with proliferative diabetic retinopathy and diabetic macular edema. Anti-vascular endothelial growth factor treatments have been hypothesized as an alternative adjunctive treatment for the management of retinal neovascularization and macular edema related with diabetic retinopathy.
There are a few reports of retinal traction detachment in patients with proliferative diabetic retinopathy and fibrovascular proliferation (although it is not frequent). However, from our clinical experience, we think that the risk of detachment only exists when there is in place a fibrovascular proliferation with retinal traction previous to the injection.
We injected ranibizumab prior to surgery in patients with severe proliferative diabetic retinopathy, that were submitted later to a posterior vitrectomy, to reduce neovascularization and minimize the risk of an intraoperatory hemorrhage caused by the manipulation of the fibrovascular membranes. In total, we already injected and submitted to surgery 15 eyes with the above mentioned condition, with excellent results. The results of the first 10 eyes were presented in the congress of the Portuguese Society of Ophthalmology (2008).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||54 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy (Ranibizumab 0.5 mg Intravitreal Injections) Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy|
|Study Start Date :||September 2010|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||December 2013|
Active Comparator: Panretinal Photocoagulation (PRP)
Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
|Procedure: Panretinal Photocoagulation (PRP)|
Group 2: Intravitreous injections of ranibizumab every 4 weeks at month-0, month-1 and month-2 that can be repeated after month-3.
|Drug: Intravitreous injection of ranibizumab|
Experimental: Ranibizumab + Panretinal Photocoagulation (PRP)
Group 3: Combination treatment of ranibizumab intravitreous injections plus PRP (2 weeks +/- 1 week after injection), at month-0, month-1 and month-2 that can be repeated after month-3.
|Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of ranibizumab|
- Regression of neovascularization [ Time Frame: 12-month treatment ]To demonstrate superiority of one of the treatment arms: ranibizumab 0.5 mg monotherapy, panretinal photocoagulation monotherapy or combination therapy (ranibizumab 0.5 mg plus panretinal photocoagulation) over a 12-month treatment period in the regression of neovascularization.
- Changes from baseline in Best-Corrected Visual Acuity [ Time Frame: 12-month treatment ]Best-Corrected Visual Acuity will be assessed during the trial (Baseline, Month 3, Month 6 and Month 12).
- Changes from baseline in macular retinal thickness by Optical Coherent Tomography [ Time Frame: 12-month treatment ]Optical Coherent Tomography will be assessed during the trial (Baseline, Month 3, Month 6 and Month 12).
- Recurrence of neovascularization [ Time Frame: 12-month treatment ]To assess if there is recurrence of neovascularization.
- Number of treatments needed [ Time Frame: 12-month treatment ]To analyse the number treatments given to each subject during the the 12-month treatment.
- Additional focal or grid laser for Diabetic Macular Edema [ Time Frame: 12 month treatment ]To assess the number of patients that received additional focal or grid laser for Diabetic Macular Edema.
- Adverse events [ Time Frame: 12-month treatment ]Drug safety profile.
- Need for vitrectomy due to occurrence of vitreous hemorrhage or retinal detachment relative to the three treatment arms. [ Time Frame: 12-month treatment ]To assess the number of subjects who needed vitrectomy due to occurrence of vitreous hemorrhage or retinal detachment relative to the three treatment arms.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01280929
|Center for Clinical Trials - Association for Innovation and Biomedical Research on Light and Image|
|Coimbra, Portugal, 3000-548|
|Espaço Médico de Coimbra|
|Coimbra, Portugal, 3030-163|
|Lisboa, Portugal, 1050-078|
|Instituto de Retina de Lisboa|
|Lisboa, Portugal, 1050-085|
|Instituto de Oftalmologia Dr. Gama Pinto|
|Lisboa, Portugal, 1169-019|
|Porto, Portugal, 4100-180|
|Hospital de São João|
|Porto, Portugal, 4200-319|
|Study Chair:||José Cunha-Vaz, MD, PhD||Association for Innovation and Biomedical Research on Light and Image|
|Principal Investigator:||João Figueira, MD||Center for Clinical Trials - Association for Innovation and Biomedical Research on Light and Image|